MedTrace Logo

Perioperative Platelet Inhibition With Acetylsalicylic Acid in Patients With Resectable Tumors of the Pancreatic Head

NCT05637567 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2023-11-13

No results posted yet for this study

Summary

This randomized, controlled clinical trial compares the perioperative treatment with acetylsalicylic acid (aspirin) in patients with cancer of the pancreatic head. The main question it aims to answer is: Do patients treated perioperatively with aspirin develop less metastasis after curative resection of pancreatic head tumors?

Participants will be asked to :

* take a daily aspirin tablet starting 1-4 weeks before surgery until 6 months after surgery
* participate in regular follow-up visits.

Conditions

  • Pancreatic Cancer Resectable

Interventions

DRUG

Acetylsalicylic acid

100 mg per os once daily

DRUG

Placebo

Placebo pill per os once daily

Sponsors & Collaborators

  • German Cancer Research Center

    lead OTHER

Principal Investigators

  • Sebastian Schoelch, MD · German Cancer Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2028-09-30
Completion
2029-03-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05637567 on ClinicalTrials.gov